Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2026-03-19 00:00:00 ET · period of report 2026-03-17 · accession 0001701247-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-19 | 2026-03-17 | ELVN | Collins Helen Louise | Chief MEDICAL Off | S - Sale+OE | $27.76 | -5,000 | 25.0K | -17% | -$138.8K |
| D | 2026-03-19 | 2026-03-17 | ELVN | Collins Helen Louise | Chief MEDICAL Off | M - OptEx | $2.48 | +5,000 | 30.0K | +20% | +$12.4K |
| D | 2026-03-19 | 2026-03-17 | ELVN | Collins Helen Louise | Chief MEDICAL Off | M - OptEx | $0.00 | -5,000 | 176.3K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-17 | S | D | 5,000 | $27.76 | 25,000 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $27.40 to $28.2278. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F4) These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. |
| 2 | Common | Common Stock | 2026-03-17 | M | A | 5,000 | $2.48 | 30,000 | D | — | — | (F2) Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. |
| 3 | Derivative | Stock Option (right to buy) | 2026-03-17 | M | D | 5,000 | $0.00 | 176,268 | D | $2.48 · — to 2031-06-17 | 5,000 Common Stock | (F5) All of the shares subject to this option are fully vested and exercisable as of the date hereof. |